A A

References

  1. The Australian Cancer Network and National Breast Cancer Centre. Clinical practice guidelines for the management of women with epithelial ovarian cancer. National Breast Cancer Centre, Camperdown, NSW, 2004
  2. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) Books – Ovarian cancer for Australia (ICD10 C56). http://www.aihw.gov.au. Accessed: May 2014
  3. Australian Insitute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). Cancer in Australia: an overview 2012. Cancer series no. 74. Cat. no. CAN 70. AIHW, Canberra, 2012
  4. Australian Institute of Health and Welfare. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. AIHW, Canberra, 2012
  5. Elattar A, Bryant A, Winter-Roach BA, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; (8):CD007565
  6. Prat J and Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014; 124(1):1-5
  7. Cancer Australia and the Royal Australian College of Obstetricians and Gynaecologists. National gynaecological cancers service delivery and resource framework. Cancer Australia, Canberra, 2011
  8. Pospísková M, Spenerová M, Pilka R, et al. Repeated chemosensitivity testing in patients with epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2010; 31(3):295-98
  9. Cancer Australia. First line chemotherapy for women with epithelial ovarian cancer: a systematic review. Cancer Australia, Surry Hills, NSW, 2013
  10. NBOCC. Multidisciplinary care in Australia: a national demonstration project in breast cancer. NBOCC, Sydney, 2003
  11. National Health and Medical Research Council (NHMRC). How to review the evidence: systematic identification and review of the scientific literature. NHMRC, Canberra, 2000
  12. Seidman JD and Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000; 31(5):539-57
  13. Winter-Roach BA, Kitchener HC and Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012; CD004706
  14. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96
  15. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83
  16. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006; 24(7):1127-35
  17. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010; 28(27):4162-9
  18. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25
  19. Bolis G, Scarfone G, Raspagliesi F, et al. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer. 2010; 46(16):2905-12
  20. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006; 98(15):1036-45
  21. Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol, 2008
  22. Aravantinos G, Fountzilas G, Bamias A, et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer. 2008; 44(15):2169-77
  23. Lhomme C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008; 26(16):2674-82
  24. Nicoletto MO, Tumolo S, Sorio R, et al. Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 17(5):986-92
  25. Reed NS, Poole CJ, Coleman R, et al. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer. 2006; 42(2):179-85
  26. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011; 29(27):3628-35
  27. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91
  28. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21(17):3194-200
  29. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9
  30. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol. 2006; 24(4):579-86
  31. Aravantinos G, Fountzilas G, Kosmidis P, et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005; 16(7):1116-22
  32. Mouratidou D, Gennatas C, Michalaki V, et al. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res. 2007; 27(1B):681-5
  33. Bezjak A, Tu D, Bacon M, et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004; 22(22):4595-603
  34. Butler L, Bacon M, Carey M, et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol. 2004; 22(12):2461-8
  35. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003; 13 Suppl 2144-8
  36. Dittrich C, Sevelda P, Salzer H, et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer. 2003; 39(8):1129-40
  37. Muthuramalingam SR, Braybrooke JP, Blann AD, et al. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. Eur J Gynaecol Oncol. 2011; 32(3):253-8
  38. Vasey PA, Atkinson R, Osborne R, et al. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer. 2006; 94(1):62-8
  39. Clamp AR, Maenpaa J, Cruickshank D, et al. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer. 2006; 94(1):55-61
  40. Minagawa Y, Kigawa J, Kanamori Y, et al. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol. 2006; 101(3):495-8
  41. Mori T, Hosokawa K, Kinoshita Y, et al. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol. 2007; 12(3):205-11
  42. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010; 20(2):240-7
  43. Fruscio R, Colombo N, Lissoni AA, et al. A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. Br J Cancer. 2008; 98(4):720-7
  44. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53
  45. Jaaback K and Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; CD005340
  46. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34-43
  47. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374(9698):1331-8
  48. Katsumata N, Yasuda M, Isonishi S, et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol 30, 2012 (suppl; abstr 5003). 2012; 30(15 Supplement):Abstract 5003
  49. Harano K, Terauchi F, Katsumata N, et al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Ann Oncol. 2014; 25(1):251-7
  50. Eisenhauer EL, Tew WP, Levine DA, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007; 106(2):381-7
  51. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2012; 30(13):1553-1561
  52. Robinson WR, Ritter J, Rogers AS, et al. Clinical trial participation is associated with improved outcome in women with ovarian cancer. Int J Gynecol Cancer. 2009; 19(1):124-8
  53. Peppercorn JM, Weeks JC, Cook EF and Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004; 363(9405):263-70
  54. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013; 14(3):236-43
  55. Burger RA, Brady MF, Bookman MA, et al. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014;
  56. Grenman S, Wiklund T, Jalkanen J, et al. A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer. 2006; 42(14):2196-9
  57. Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007; 25(27):4187-93
  58. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-65
  59. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011; 22(6):1346-52
  60. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008; 26(34):5530-6
  61. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63
  62. Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004; 94(2):540-9
  63. Hilpert F, du Bois A, Greimel ER, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. Ann Oncol. 2007; 18(2):282-7
  64. Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 109(3):353-8
  65. Barrett SV, Paul J, Hay A, et al. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Annals of Oncology. 2008; 19(5):898-902
  66. Matthews KS, Straughn JM, Jr., Kemper MK, et al. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol. 2009; 112(2):389-93
  67. Suh DH, Kim HS, Chung HH, et al. Body mass index and survival in patients with epithelial ovarian cancer. Journal of Obstetrics & Gynaecology Research. 2012; 38(1):70-6
  68. Hanna R, Poniwierski M, Laskey R, et al. Predictors and effects of reduced relative dose intensity in women receiving their primary course of chemotherapy for ovarian cancer. Gynecologic Oncology. 2011; 120S98
  69. Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006; 107(7):1520-4
  70. Au-Yeung G, Webb PM, DeFazio A, et al. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014; 133(1):16-22
  71. Laskey RA, Poniewierski MS, Lopez MA, et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecologic Oncology. 2012; 125(3):625-630
  72. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006; 98(22):1655-63
  73. Raja FA, Chopra N and Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012; 23(Suppl 10):X118-27
  74. Katsumata N. Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor. Ann Oncol. 2011; 22(Suppl 8):viii29-viii32
  75. Robinson WR and Beyer J. Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer. Int J Gynecol Cancer. 2010; 20(1):70-4
  76. Vergote I, du Bois A, Amant F, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol. 2013; 128(1):6-11
  77. Kehoe. S, Hook. J, Nankivell. M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. J Clin Oncol 31, 2013 (suppl; abstr 5500) 2013;
  78. Polcher M, Mahner S, Ortmann O, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep. 2009; 22(3):605-13
  79. Sundararajan V, Hershman D, Grann VR, et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002; 20(1):173-8
  80. Jordan S, Steer C, DeFazio A, et al. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study. Gynecol Oncol. 2013; 129(2):310-7
  81. Tew W, Java J, Chi D, et al. Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). J Clin Oncol. 2010; 28(15S):Abstract 5030
  82. Hurria A, Browner IS, Cohen HJ, et al. Senior adult oncology. J Natl Compr Canc Netw. 2012; 10(2):162-209
  83. Timmers PJ, Zwinderman AH, Teodorovic I, et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer. 2009; 19(1):88-93
  84. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Annals of Oncology. 2010; 21(12):2377-81
  85. Mereu L, Tateo S, Klersy C, et al. Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy. International Journal of Gynecological Cancer. 2009; 19(1):79-83
  86. Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemotherapy and Pharmacology. 2005; 56(1):91-96
  87. Hourdequin KC, Schpero WL, McKenna DR, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol. 2013; 24(12):2952-62
  88. National Health and Medical Research Council (NHMRC). NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Commonwealth of Australia, 2009